Rhenman & Partners Asset Management AB Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

Posted by Stanley Muller on Jun 13th, 2026

Rhenman & Partners Asset Management AB bought a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 250,000 shares of the company’s stock, valued at approximately $8,642,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its position in IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after purchasing an additional 580 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of IDEAYA Biosciences during the 3rd quarter valued at $38,000. ANTIPODES PARTNERS Ltd lifted its position in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new stake in shares of IDEAYA Biosciences during the 3rd quarter valued at $58,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the 4th quarter valued at $61,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDYA has been the subject of a number of recent research reports. The Goldman Sachs Group increased their price objective on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, April 14th. Truist Financial set a $65.00 price objective on IDEAYA Biosciences in a research report on Monday, April 13th. Wall Street Zen upgraded IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. Wedbush reiterated an “outperform” rating and set a $58.00 price objective on shares of IDEAYA Biosciences in a research report on Friday. Finally, Guggenheim increased their price objective on IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.69.

Read Our Latest Stock Analysis on IDYA

IDEAYA Biosciences Stock Up 0.5%

IDYA opened at $28.98 on Friday. The stock has a fifty day moving average of $29.89 and a 200-day moving average of $32.49. The firm has a market capitalization of $2.55 billion, a P/E ratio of -18.11 and a beta of -0.05. IDEAYA Biosciences, Inc. has a 12-month low of $20.50 and a 12-month high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. The firm’s quarterly revenue was down 39.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.82) EPS. On average, analysts expect that IDEAYA Biosciences, Inc. will post -4.27 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

(Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.